colorectal liver metastases
Conditions
Interventions
None listed
Sponsors
Kyoto University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: a) Patients with synchronous colorectal liver metastases who have disappearing liver metastases (DLM) which are detected by CT and EOB-MRI (3T, slice thickness of hepatobiliary phase with 2mm or less). b) The lesions were detected by EOB-MRI (3T, slice thickness of hepatobiliary phase with 2mm or less) before or within a month after a beginning of the chemotherapy for synchronous colorectal liver metastases. c) Patients who underwent thoracoabdominal CECT scan before or within a month after the beginning of the chemotherapy for synchronous colorectal liver metastases. d) RAS mutation, BRAF mutation and MSI status of a primary colorectal cancer are known or planned to be tested. e) Patients without allergic reaction to contrast medium and can undergo EOB-MRI. f) Patients who are expected to survive more than 6 months. g) Patients aged 18 years or older. h) Patients without a possibility of pregnancy.
Exclusion criteria
Exclusion criteria: Patients who were diagnosed with any malignant tumors other than colorectal cancer and carcinoma in situ within the past two years.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| negative predictive value for no residual tumor | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival intrahepatic recurrence free survival recurrence free survival factors predicting for no residual tumor | — |
Countries
Japan
Contacts
Public ContactKojiro Nakamura
National Hospital Organization Kyoto Medical Center Department of Surgery
Outcome results
None listed